The improvement in glucose control was in line with that reported during and immediately after COVID-19 pandemic lockdown in people with type 1 diabetes or, less consistently, with T2D, particularly patients using insulin (26–28). The gene discussed is INS; the disease is type 2 diabetes mellitus.